Semaglutide is a GLP-1 receptor agonist used in the management of type 2 diabetes and for weight management in eligible patients. As a generic formulation, this injection offers a cost-effective alternative for healthcare providers and sourcing buyers seeking to diversify their pharmaceutical supply chain. The product is currently listed as to be launched, indicating that commercial availability is pending regulatory and production milestones.
Lotus Pharmaceutical, headquartered in Tashkent, Uzbekistan, has been operational since 1966 and specializes in pharmaceutical manufacturing. The company presents semaglutide as part of its product portfolio, targeting international buyers who require reliable sourcing for essential therapeutic agents. This entry represents a potential addition to a buyer’s procurement options for metabolic health treatments. Standard pharmaceutical procurement practices should be followed to verify registration status and supply timelines.